Michael Ulz, an analyst from Morgan Stanley, maintained the Hold rating on Arrowhead Pharmaceuticals. The associated price target remains the same with $45.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Michael Ulz has given his Hold rating due to a combination of factors surrounding Arrowhead Pharmaceuticals. The recent FDA approval of Redemplo for familial chylomicronemia syndrome (FCS) was anticipated and came with a clean label, which is a positive sign. However, while the label is favorable compared to competitors, the pricing strategy and the limited market size for FCS patients, who are often undiagnosed, present challenges.
Looking forward, the potential expansion into the severe hypertriglyceridemia (SHTG) market represents a significant opportunity for Arrowhead. The ongoing Phase 3 trials are crucial, with results expected in the third quarter of 2026, which could influence future valuations. Despite these prospects, the current uncertainties and market conditions justify a cautious Hold stance until more data becomes available.